Table 1 Characteristics of the studies included in the meta-analysis
References | Study design | Participating centers (N.) | Patients (N.) | Mean age IVIgGM/control (years) | Duration of treatment (days) | Daily dose (g/kg) | Control | Severity score (IgM/control) | Follow-up (days) |
|---|---|---|---|---|---|---|---|---|---|
Behre et al. [18] | RCT | 2 | 52 | 50/55 | 3 | 0.31 | 5% HAS | NR/NR | 28 |
Brunne et al. [12] | RCT | 1 | 38 | 61/66 | 3 | 0.25 | HAS | SOFA score 11(4)/11(5) | 28 |
Buda et al. [19] | ROS | 1 | 66 | 62.9/68.6 | 3 | 0.25 | Placebo | APACHE II 20.5(5.8)/21.5(5.4) | 70 |
Cavazzuti et al. [8] | ROS | 1 | 168 | 68.9/71.7 | 3 | 0.25 | Placebo | SOFA score 9.5(3.3)/8.6(3.6) | 30 |
Giamarellos-Bourboulis et al. [9] | POS | 63 | 200 | 51.9/54.2 | 5 | > 0.25 | Placebo | APACHE II 19.6(6.9)/20.7(6.6) | 28 |
Hentrich et al. [20] | RCT | 6 | 206 | 48.8/51.0 | 3 | 0.31 | HAS | NR/NR | 28 |
Just et al. [21] | RCT | 1 | 29 | NR/NR | 1.5 | NR | Placebo | NR/NR | ICU |
Karatzas et al. [22] | RCT | 1 | 68 | 50.5/50.7 | 3 | 0.25 | Placebo | APACHE II 21.3 (7.2)/23.5 (7.9) | 28 |
Reith et al. [23] | RCT | 1 | 67 | NR/NR | 3 | 0.2 | Placebo | NR/NR | ICU |
Rodriguez et al. [24] | RCT | 1 | 37 | NR/NR | 5 | 0.35 | 5% HAS | NR/NR | 30 |
Rodriguez et al. [25] | RCT | 7 | 56 | 61.3/65.9 | 5 | 0.35 | 5% HAS | APACHE II 16.1 (5.9)/15.2 (6.1) | ICU |
Schedel et al. [26] | RCT | 1 | 55 | 46/37 | 3 | 0.285 | Placebo | APACHE II 30/24 | 42 |
Spannbrucker et al. [27] | RCT | 1 | 50 | 50.8/54.5 | 3 | 0.15 | Placebo | NR/NR | 12 |
Toth et al. [13] | RCT | 1 | 33 | 56/60 | 3 | 0.25 | Placebo | APACHE II 26 (5.25)/25 (5.5) | 28 |
Tugrul et al. [28] | RCT | 1 | 42 | 42/49.3 | 3 | 0.25 | Placebo | APACHE II 10.5 (4.6)/14 (8.5) | 28 |
Vogel et al. [29] | RCT | 1 | 50 | NR/NR | NR | NR | Placebo | NR/NR | ICU |
Welte et al. [14] | RCT | 3 | 160 | 63.7/65.5 | 5 | NR | Placebo | SOFA score 9.7(3.8)/10.8(3.5) | 28 |
Wesoly et al. [30] | RCT | 1 | 35 | 44.7/54.8 | 3 | 0.25 | Placebo | Sepsis score 14.8 (2.5)/16.3 (3.6) | ICU |
Yavuz et al. [31] | ROS | 1 | 118 | 54.5/59.5 | 3 | 0.25 | Placebo | APACHE II 27.1/27 | 28 |